We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Nevro Corp (NVRO) USD0.001

Sell:$3.99 Buy:$4.00 Change: $0.20 (5.31%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$3.99
Buy:$4.00
Change: $0.20 (5.31%)
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Sell:$3.99
Buy:$4.00
Change: $0.20 (5.31%)
Market closed |  Prices as at close on 24 December 2024 | Switch to live prices |
Deal now Deal for just £11.95 per trade in a Stocks and Shares ISA, Lifetime ISA , SIPP or Fund and Share Account
Deal now
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Nevro Corp. is a global medical device company. The Company is focused on delivering solutions that continue to set the standard for enduring patient outcomes in chronic pain treatment. Its comprehensive HFX spinal cord stimulation 3 (SCS) platform includes the Senza SCS system and support services for the treatment of chronic pain of the trunk and limb and painful diabetic neuropathy. It has developed and commercialized its HFX spinal cord stimulation (SCS) platform, which includes the Senza SCS system, an evidence-based neuromodulation system for the treatment of chronic pain, with the Senza HFX iQ platform. Its HFX solution delivers a range of waveforms, including its paresthesia-free 10 kHz Therapy. Its 10 kHz Therapy is designed to deliver neuromodulation solutions for treating chronic pain. Its products include Senza II SCS System, Senza Omnia SCS System, Senza Omnia upgrade, Omnia Powered by HFX Connect, Senza HFX iQ System, and Surpass Surgical Lead.

Contact details

Address:
1800 Bridge Parkway
REDWOOD CITY
94065
United States
Telephone:
+1 (650) 2510005
Website:
https://www.nevro.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
NVRO
ISIN:
US64157F1030
Market cap:
$148.76 million
Shares in issue:
37.47 million
Sector:
Health Care Equipment
Exchange:
New York Stock Exchange
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • D. Keith Grossman
    Executive Chairman of the Board
  • Kevin Thornal
    President, Chief Executive Officer, Director
  • Roderick Macleod
    Chief Financial Officer, Senior Vice President
  • Christopher Christoforou
    Chief Operating Officer
  • David Caraway
    Senior Vice President, Chief Medical Officer
  • Donald Middlebrook
    Senior Vice President - Clinical, Regulatory and Quality
  • Kashif Rashid
    Senior Vice President - Corporate Development, Chief Legal Officer
  • Greg Siller
    Senior Vice President, Chief Commercial Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Options

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.